Table 1.

Baseline characteristics of included studies

Prognostic studiesPharmacogenetic studies
Number of studies (%)Number of studies (%)
Total number of studies48 (100)12 (100)
Source of patients
 Case series33 (69)3 (25)
 Cases from case–control risk studies11 (23)0 (0)
 Secondary analysis of clinical trial data4 (9)9 (75)
 Developed cancer after entering cohort study1 (2)0 (0)
Type of patient
 Caucasian predominant sample33 (69)11 (92)
 Asian predominant sample14 (29)1 (8)
Location of study
 North and Central American14 (29)5 (42)
 South American1 (2)0 (0)
 European18 (4)6 (50)
 East Asian13 (27)1 (8)
 South Asian1 (2)0 (0)
 Australian1 (2)0 (0)
Type of sample
 Blood38 (79)11 (92)
 Frozen normal tissue2 (4)0 (0)
 Frozen tumor tissue5 (10)0 (0)
 FFPE adjacent tissue4 (8)0 (0)
 FFPE tumor tissue4 (8)1 (8)
Disease site
 Breast6 (13)2 (17)
 Colorectal (GI)7 (15)3 (25)
 Gastroesophageal (upper GI)9 (19)1 (8)
 Genitourinary4 (8)0 (0)
 Gynecologic8 (17)2 (17)
 Lung4 (8)0 (0)
 Other (includes liver, melanoma, AML, CML, NHL, head, and neck)10 (21)4 (33)
Selection of polymorphisms
 Any VEGF42 (88)9 (75)
VEGF −2578C>A20 (42)6 (50)
 VEGF −1154G>A13 (27)5 (42)
 VEGF −460C>T19 (40)6 (50)
 VEGF +405G>C33 (69)9 (75)
 VEGF +936C>T31 (65)9 (75)
 Any KDR/VEGFR2 or FLT1/VEGFR18 (17)6 (50)
 Any Endostatin, FGF2 or FGFR5 (10)0 (0)
Type of analysis
 Univariate analysis only13 (27)9 (75)
  Observational study12 (25)1 (8)
  Clinical trial1 (2)8 (67)
 Multivariate analysis conducted35 (73)3 (25)
  Observational study32 (67)2 (17)
  Clinical trial3 (6)1 (8)
Type of predictive analysis
 Survival outcomesNot applicable9 (75)
 Toxicity10 (83)

Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; FFPE, formalin-fixed paraffin-embedded; GI, gastrointestinal; NHL, non-Hodgkin lymphoma.